BRPI0512993A - uso de um antagonista de pr, kit farmaceuticamente últil, e, método de contracepção em uma fêmea em idade de parto - Google Patents

uso de um antagonista de pr, kit farmaceuticamente últil, e, método de contracepção em uma fêmea em idade de parto

Info

Publication number
BRPI0512993A
BRPI0512993A BRPI0512993-1A BRPI0512993A BRPI0512993A BR PI0512993 A BRPI0512993 A BR PI0512993A BR PI0512993 A BRPI0512993 A BR PI0512993A BR PI0512993 A BRPI0512993 A BR PI0512993A
Authority
BR
Brazil
Prior art keywords
contraception
pharmaceutically useful
antagonist
female
childbirth
Prior art date
Application number
BRPI0512993-1A
Other languages
English (en)
Inventor
Gary Sondermann Grubb
Ginger Dale Constantine
Andrew Fensome
Casey Cameron Mccomas
Edward George Melenski
Michael Anthony Marella
Jay Edward Wrobel
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35106665&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0512993(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0512993A publication Critical patent/BRPI0512993A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

USO DE UM ANTAGONISTA DE PR, KIT FARMACEUTICAMENTE úTIL, E, MéTODO DE CONTRACEPçãO EM UMA FêMEA EM IDADE DE PARTO Um método de contracepção é fornecido que envolve a liberação de 21 a 27 dias consecutivos de um ou mais antagonistas de PR na ausência de uma progestina, estrogênio ou outro composto esteróide, seguido por 1 a 7 dias sem nenhum agente ativo. Também é descrito um kit farmaceuticamente útil para facilitar a liberação deste regime.
BRPI0512993-1A 2004-07-07 2005-07-06 uso de um antagonista de pr, kit farmaceuticamente últil, e, método de contracepção em uma fêmea em idade de parto BRPI0512993A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58588304P 2004-07-07 2004-07-07
US67613505P 2005-04-29 2005-04-29
PCT/US2005/023798 WO2006017075A1 (en) 2004-07-07 2005-07-06 Progesterone receptor antagonist contraceptive regimens and kits

Publications (1)

Publication Number Publication Date
BRPI0512993A true BRPI0512993A (pt) 2008-04-22

Family

ID=35106665

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0512993-1A BRPI0512993A (pt) 2004-07-07 2005-07-06 uso de um antagonista de pr, kit farmaceuticamente últil, e, método de contracepção em uma fêmea em idade de parto

Country Status (20)

Country Link
US (1) US20060009509A1 (pt)
EP (1) EP1773323A1 (pt)
JP (1) JP2008505906A (pt)
KR (1) KR20070039912A (pt)
AR (1) AR049664A1 (pt)
AU (1) AU2005271974A1 (pt)
BR (1) BRPI0512993A (pt)
CA (1) CA2571198A1 (pt)
CR (1) CR8800A (pt)
EC (1) ECSP077131A (pt)
GT (1) GT200500186A (pt)
IL (1) IL180238A0 (pt)
MX (1) MXPA06014580A (pt)
NO (1) NO20070377L (pt)
PA (1) PA8638501A1 (pt)
PE (1) PE20060485A1 (pt)
RU (1) RU2006144069A (pt)
SV (1) SV2006002166A (pt)
TW (1) TW200605880A (pt)
WO (1) WO2006017075A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407101B1 (en) * 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6509334B1 (en) * 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
GB0121285D0 (en) * 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
WO2006014476A1 (en) 2004-07-07 2006-02-09 Wyeth Cyclic progestin regimens and kits
US8865200B2 (en) 2004-07-09 2014-10-21 Laboratoire Hra Pharma Sustained release compositions containing progesterone receptor modulators
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
AR053710A1 (es) 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
AR056968A1 (es) 2005-04-11 2007-11-07 Xenon Pharmaceuticals Inc Compuestos espiro-oxindol y composiciones farmacéuticas
WO2008060789A2 (en) 2006-10-12 2008-05-22 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
JO3032B1 (ar) 2008-10-17 2016-09-05 Xenon Pharmaceuticals Inc مركبات سبيرو – اوكسندول وإستعمالاتها كعوامل علاجية.
CA2741024A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
BRPI1014035A2 (pt) 2009-04-14 2016-04-12 Hra Pharma Lab método para contracepção.
BRPI1011784A2 (pt) 2009-06-18 2016-03-22 Pfizer compostos bicíclicos e tricíclicos como inibidores de kat ii
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
KR20120099429A (ko) 2009-10-14 2012-09-10 제논 파마슈티칼스 인크. 스피로-옥스인돌 화합물의 합성 방법
WO2011106729A2 (en) 2010-02-26 2011-09-01 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
US9375437B2 (en) 2010-06-18 2016-06-28 Lipocine Inc. Progesterone containing oral dosage forms and kits
JP2013544277A (ja) 2010-12-01 2013-12-12 ファイザー・インク Ｋａｔｉｉ阻害剤
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
US9522154B2 (en) 2013-03-14 2016-12-20 Laboratoire Hra-Pharma Method for scheduling ovulation
WO2016127068A1 (en) 2015-02-05 2016-08-11 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
AU2016284459B2 (en) 2015-06-22 2021-12-23 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407101B1 (en) * 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6444668B1 (en) * 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6509334B1 (en) * 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors

Also Published As

Publication number Publication date
CA2571198A1 (en) 2006-02-16
SV2006002166A (es) 2006-05-09
TW200605880A (en) 2006-02-16
ECSP077131A (es) 2007-02-28
EP1773323A1 (en) 2007-04-18
US20060009509A1 (en) 2006-01-12
PA8638501A1 (es) 2006-07-03
AR049664A1 (es) 2006-08-23
CR8800A (es) 2007-08-28
NO20070377L (no) 2007-02-07
AU2005271974A1 (en) 2006-02-16
GT200500186A (es) 2006-03-02
IL180238A0 (en) 2007-07-04
JP2008505906A (ja) 2008-02-28
RU2006144069A (ru) 2008-08-20
PE20060485A1 (es) 2006-06-24
WO2006017075A1 (en) 2006-02-16
KR20070039912A (ko) 2007-04-13
MXPA06014580A (es) 2007-03-23

Similar Documents

Publication Publication Date Title
BRPI0512993A (pt) uso de um antagonista de pr, kit farmaceuticamente últil, e, método de contracepção em uma fêmea em idade de parto
BRPI0512991A (pt) uso de uma progestina, kit farmaceuticamente útil adaptado para a administração oral diária, e, método de contracepção em uma fêmea em idade de parto
ES2602823T3 (es) Proceso para la preparación de drospirenona
PE20120860A1 (es) Combinacion farmaceutica que comprende levonorgestrel en combinacion con piroxicam, indometacina o diclofenaco
MX2009004616A (es) Metodos de tratamiento hormonal que utilizan regimenes de ciclo extendido de dosis ascendente.
BR112012007412A2 (pt) tabletes transformáveis de forma oral.
BRPI0514474A (pt) multiparticulados
DE602004017045D1 (de) Graduierte östrogen-kontrazeptiva
AR057060A1 (es) Composiciones de tanaproget que contienen etinil estradiol
BRPI0709057C1 (pt) veículo mucoso bioadesivo de lenta liberação, método para preparar um veículo mucoso bioadesivo de lenta liberação, e, uso do veículo mucoso bioadesivo de lenta liberação
PE20061415A1 (es) Composicion farmaceutica que contiene gestagenos y/o estrogenos y 5-metil-(6s)-tetrahidrofolato
CL2007001961A1 (es) Composicion farmaceutica que contiene a) 2,0 mg de dienogest y 0,015 mg de etinilestradiol y (6s)-5-metil-tetrahidrofolato y uno o mas excipiente/vehiculos; kit; uso para la anticoncepcion femeneina y reducir el riesgo d malformaciones congenitas debidas a la falta de folato en el embarazo.
ITMI20040367A1 (it) Processo per la preparazione di drospirenone
SG166107A1 (en) Quadraphasic continuous graduated estrogen contraceptive
CO5631449A2 (es) Nuevos esteres de etonogestrel
PE20080995A1 (es) 18-metil-19-nor-androst-4-en-17,17-espiroeteres(18-metil-19-nor-20-espirox-4-en-3-onas), asi como preparaciones farmaceuticas que los contienen
PE20060275A1 (es) Composicion farmaceutica que contiene progestina y estrogeno para el tratamiento de trastorno disforico premenstrual
BRPI0408944A (pt) método para fornecer um benefìcio de redução de esteróide com um inibidor de ciclooxigenase-2 e composições com este
PE20090805A1 (es) COMBINACION DE DROSPIRENONA Y 17ß-ESTRADIOL COMO CONTRACEPTIVO ORAL
BR0215064A (pt) Agonistas receptores seletivos de dopamina d3 para o tratamento de disfunção sexual
CL2004001317A1 (es) Composicion farmaceutica que comprende el antagonista de receptores de progesterona 11b-(4-acetilfenil)-17b-hidroxi-17 alfa-(1,1,2,2,2-pentafluoroetil)-estra-4,9-dien-3-ona y un antiestrogeno puro; y su uso para tratar una enfermedad dependiente de h
PE20010579A1 (es) Mesoprogestinas (modulares de receptores de progesterona) como componentes de anticonceptivos femeninos
AR018313A1 (es) Kit anticonceptivo que comprende medios para la administracion diaria de un agente anticonceptivo, uso de un compuesto esteroide que tiene un perfil deactividad que combina inherentemente las actividades progestagenicas y estrogenicas y un metodo anticonceptivo
PE20080541A1 (es) Forma farmacologica peroral para la anticoncepcion
AR069195A1 (es) Uso de un gestageno en combinacion con un estrogeno y uno o varios excipientes/portadores farmaceuticamente aceptables para la anticoncepcion oral sin lactosa

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]